What AstraZeneca’s KALOS and LOGOS data reveal about triple inhaler therapy in asthma

AstraZeneca’s KALOS and LOGOS trials highlight triple inhaler therapy gains in asthma. Explore what this means for guidelines and payers.

AstraZeneca’s KALOS and LOGOS trials highlight triple inhaler therapy gains in asthma. Explore what this means for guidelines and payers.